1. Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade.
- Author
-
Rwandamuriye, Francois Xavier, Wang, Tao, Zhang, Hanfu, Elaskalani, Omar, Kuster, Jorren, Ye, Xueting, Vitali, Breana, Schreurs, Juliët, Orozco Morales, M. Lizeth, Norret, Marck, Evans, Cameron W., Zemek, Rachael M., Iyer, K. Swaminathan, Lesterhuis, W. Joost, and Wylie, Ben
- Subjects
TOLL-like receptor agonists ,IMMUNE checkpoint proteins ,IMMUNOMODULATORS ,TUMOR growth ,TOLL-like receptors - Abstract
Toll-like receptor (TLR) agonists are being developed as anti-cancer therapeutics due to their potent immunostimulatory properties. However, clinical trials testing TLR agonists as monotherapy have often failed to demonstrate significant improvement over standard of care. We hypothesized that the anti-cancer efficacy of TLR agonist immunotherapy could be improved by combinatorial approaches. To prevent increased toxicity, often seen with systemic combination therapies, we developed a hydrogel to deliver TLR agonist combinations at low doses, locally, during cancer debulking surgery. Using tumor models of WEHI 164 and bilateral M3–9-M sarcoma and CT26 colon carcinoma, we assessed the efficacy of pairwise combinations of poly(I:C), R848, and CpG in controlling local and distant tumor growth. We show that combination of the TLR3 agonist poly(I:C) and TLR7/8 agonist R848 drives anti-tumor immunity against local and distant tumors. In addition, combination of local poly(I:C) and R848 sensitized tumors to systemic immune checkpoint blockade, improving tumor control. Mechanistically, we demonstrate that local therapy with poly(I:C) and R848 recruits inflammatory monocytes to the tumor draining lymph nodes early in the anti-tumor response. Finally, we provide proof of concept for intraoperative delivery of poly(I:C) and R848 together via a surgically applicable biodegradable hydrogel. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF